Should We Be Screening for SARS-CoV-2 in IBD Patients Before Initiation of Biologic Therapy?

Hashash, Jana G.; Jabak, Suha; Francis, Fadi; Regueiro, Miguel

doi:10.1093/ibd/izaa173

Cited by 2 publications

(10 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is known that this therapy is responsible for decreasing the body's response to microorganisms, resulting in these patients being more susceptible to infections. ,e higher According to research, IBD patients have mortality rates and a risk of acquiring severe forms that are similar to those of the general population for the same age range [150].…”

Section: Gastro-intestinal Diseasesmentioning

confidence: 99%

“…In a study by Wisniewski et al, IBD patients are three times more likely to develop viral diseases, including viruses like herpes simplex, Epstein-Barr, varicella-zoster, and cytomegalovirus [150,191]. Patients with IBD due to treatment with antitumor necrosis factor (anti-TNF) are twice as likely to develop opportunistic infections [150,192]. According to the evidence so far, IBD patients do not present a significantly higher risk of contracting COVID-19 than the overall population [150,[193][194][195].…”

Section: Neurological Diseases Covid-19 Patients Can Develop Amentioning

confidence: 99%

“…Patients with IBD due to treatment with antitumor necrosis factor (anti-TNF) are twice as likely to develop opportunistic infections [150,192]. According to the evidence so far, IBD patients do not present a significantly higher risk of contracting COVID-19 than the overall population [150,[193][194][195].…”

Section: Neurological Diseases Covid-19 Patients Can Develop Amentioning

confidence: 99%

“…Furthermore, in patients with both IBD and infection with the novel coronavirus, immunosuppressive treatment can be administered after three days of being afebrile and remission of symptoms. Ten days following the positive rapid test result, immunosuppressive treatment may be given to individuals with asymptomatic viral disease [150]. Individuals presenting with multiple sclerosis (MS) are more susceptible to contracting the novel coronavirus since MS is a chronic, inflammatory disease.…”

Section: Neurological Diseases Covid-19 Patients Can Develop Amentioning

confidence: 99%

“…The higher vulnerability to this viral infection in this group of individuals is not yet sufficiently supported by research. According to research, IBD patients have mortality rates and a risk of acquiring severe forms that are similar to those of the general population for the same age range [ 150 ].…”

Section: Comorbidities and Associated Diseasesmentioning

confidence: 99%

See 4 more Smart Citations

Comorbidities, Associated Diseases, and Risk Assessment in COVID-19—A Systematic Review

Fitero

Bungău

Ţiţ

et al. 2022

International Journal of Clinical Practice

View full text Add to dashboard Cite

It is considered that COVID-19’s pandemic expansion is responsible for the particular increase in deaths, especially among the population with comorbidities. The health system is often overwhelmed by the large number of cases of patients addressing it, by the regional limitation of funds, and by the gravity of cases at subjects suffering from this pathology. Several associated conditions including diabetes, cardiovascular illnesses, obesity, persistent lung condition, neurodegenerative diseases, etc., increase the mortality risk and hospitalization of subjects suffering from COVID-19. The rapid identification of patients with increased risk of death from the SARS-CoV-2 virus, the stratification in accordance with the risk and the allocation of human, financial, and logistical resources in proportion must be a priority for health systems worldwide.

show abstract

Section: Gastro-intestinal Diseasesmentioning

confidence: 99%